dasotraline-hcl

Description: Dasotraline, formerly known as SEP-225, 289, is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that is under development by Sunovion for clinical use. The drug is no longer being developed for major depressive disorder (MDD), but is still under investigation for the treatment of attention-deficit hyperactivity disorder (ADHD) and eating disorders.

References: Koblan KS, Hopkins SC, Sarma K, Gallina N, Jin F, Levy-Cooperman N, SchoedelKA, Loebel A. Assessment of human abuse potential of dasotraline compared tomethylphenidate and placebo in recreational stimulant users. Drug Alcohol Depend.2016 Feb 1; 159:26-34. doi: 10.1016/j.drugalcdep.2015.10.029. Epub 2015 Dec 3.PubMed PMID: 26794682.